Want to see KYMR full AI Analyst Report?
KYMR Stock Chart & Stats
$125.55
-$0.08(-0.07%)
At close: 4:00 PM EDT
$125.55
-$0.08(-0.07%)
Day’s Range― - ―
52-Week Range$55.26 - $130.05
Previous CloseN/A
Volume157.52K
Average Volume (3M)804.64K
Market Cap
$8.99B
Enterprise Value$10.65B
Total Cash (Recent Filing)$690.99M
Total Debt (Recent Filing)$82.22M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Oct 29, 2026EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding83,150,620
10 Day Avg. Volume886,314
30 Day Avg. Volume804,643
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue101.40
Enterprise Value/Gross Profit99.42
Enterprise Value/Ebitda-36.53
Forecast
1Y Price Target
$141.50Price Target Upside12.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-3.86
Revenue Forecast (FY)$104.80M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Cash RunwayLow leverage and substantial liquidity give Kymera financial flexibility to fund a large clinical portfolio without immediate dependence on debt or equity markets. The runway into 2029 supports continued development through important readouts and allows management to plan programs over multiple years.
Accelerated Lead-program ExecutionCompleting a pivotal-enabling study ahead of schedule indicates effective clinical execution and may bring important efficacy and safety evidence closer. Earlier data and Phase III planning can improve development efficiency, support partner engagement, and accelerate potential commercialization of KT-621.
Broad Partnered Pipeline DevelopmentProgress across partnered and internally advanced programs reduces reliance on a single clinical asset and creates multiple opportunities for future milestones, licensing economics, and product development. A continuing cadence of new clinical candidates also supports longer-term pipeline replenishment.
Bears Say
Heavy Cash Burn And Persistent LossesKymera currently consumes substantial cash while generating deeply negative operating results, so its financial profile depends on maintaining liquidity and achieving clinical or partnership progress. Accelerating development spending could shorten the effective runway if programs require more capital than planned.
Non-recurring And Milestone-dependent RevenueRevenue is concentrated in episodic partner payments rather than recurring product sales, making reported results volatile and dependent on clinical and contractual milestones. This limits near-term revenue visibility and leaves future cash inflows sensitive to pipeline execution and partner decisions.
Clinical Readout Uncertainty In Atopic DermatitisElevated placebo responses can reduce the observable treatment effect and make trial outcomes harder to interpret, even when a candidate has biological activity. This creates ongoing execution risk for KT-621, potentially affecting confidence in efficacy, timing of decisions, and later pivotal development.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $55.26 and its highest was $130.05 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $8.99B.
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 7 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.713 by $0.093.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -1.27.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 83,150,620 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.713. Following the earnings report the stock price went up 1.044%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.50 (12.70% Upside)
$141.50 (12.70% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 383.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $744.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.2%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.53%
12-Months-Change
Fundamentals
Return on Equity
-21.50%
Trailing 12-Months
Asset Growth
45.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kymera Therapeutics
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial operational momentum: accelerated Phase 2b enrollment for KT-621, near-term KT-579 translational readout, partnership milestones that delivered $65M in Q2, and a strong balance sheet (~$1.5B) providing runway into 2029. At the same time, the company faces elevated near-term cash deployment (R&D up 22% QoQ), industry-wide challenges such as higher placebo responses in AD, a competitive STAT6 landscape, and limited near-term recurring revenue after recognition of deferred revenues. Overall, the positives — faster-than-expected enrollment, multiple upcoming data catalysts, partnership payments, and a solid cash position — meaningfully outweigh the risks and uncertainties discussed on the call.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$141.50
▲(12.70% Upside)
Technical Analysis
IDEAYA Biosciences
―
Oric Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Tango Therapeutics
―
Ownership Overview
11.97% Insiders
36.49% Mutual Funds
0.01% Other Institutional Investors
36.25% Public Companies and
Individual Investors